JP7133229B2 - 糖尿病を治療するためのシステム、組成物および方法 - Google Patents

糖尿病を治療するためのシステム、組成物および方法 Download PDF

Info

Publication number
JP7133229B2
JP7133229B2 JP2019542088A JP2019542088A JP7133229B2 JP 7133229 B2 JP7133229 B2 JP 7133229B2 JP 2019542088 A JP2019542088 A JP 2019542088A JP 2019542088 A JP2019542088 A JP 2019542088A JP 7133229 B2 JP7133229 B2 JP 7133229B2
Authority
JP
Japan
Prior art keywords
insulin
glucagon
composition
combination
molar ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505429A (ja
JP2020505429A5 (enExample
Inventor
アラン チャーリントン
デイヴィッド マグス
ソウミトラ ゴーシュ
クリストファー エイ ローズ
ジュイ－チェン リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2020505429A publication Critical patent/JP2020505429A/ja
Publication of JP2020505429A5 publication Critical patent/JP2020505429A5/ja
Application granted granted Critical
Publication of JP7133229B2 publication Critical patent/JP7133229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019542088A 2017-02-03 2018-02-02 糖尿病を治療するためのシステム、組成物および方法 Active JP7133229B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762454613P 2017-02-03 2017-02-03
US62/454,613 2017-02-03
PCT/US2018/016647 WO2018144867A1 (en) 2017-02-03 2018-02-02 Systems, compositions and methods for treating diabetes

Publications (3)

Publication Number Publication Date
JP2020505429A JP2020505429A (ja) 2020-02-20
JP2020505429A5 JP2020505429A5 (enExample) 2021-03-11
JP7133229B2 true JP7133229B2 (ja) 2022-09-08

Family

ID=63041127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542088A Active JP7133229B2 (ja) 2017-02-03 2018-02-02 糖尿病を治療するためのシステム、組成物および方法

Country Status (6)

Country Link
US (3) US11357829B2 (enExample)
EP (2) EP3576748B1 (enExample)
JP (1) JP7133229B2 (enExample)
CN (2) CN110446496A (enExample)
ES (2) ES2944544T3 (enExample)
WO (1) WO2018144867A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617832B2 (en) 2016-08-17 2023-04-04 International Business Machines Corporation Portal system-based bionic pancreas
WO2020130751A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
FI4069278T3 (fi) * 2019-12-06 2025-07-16 Dr Mary Morris & Ass Llc Menetelmiä ja koostumuksia tyypin 1 diabeteksen ehkäisemiseksi
CA3186427A1 (en) * 2020-06-11 2021-12-16 Abvance Therapeutics Inc. Systems, devices, compositions and methods for treating diabetes
EP4178606B1 (en) * 2020-07-07 2025-09-17 The Regents of University of California Therapeutic hybrid microneedle patch for the delivery of insulin and glucagon
WO2022173807A2 (en) 2021-02-09 2022-08-18 The Trustees Of Indiana University Conformationally constrained glucagon analogues and their use in glucagon-single chain insulin fusion proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514990A (ja) 2002-12-27 2006-05-18 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物および方法
JP2014507484A (ja) 2011-03-10 2014-03-27 ゼリス ファーマシューティカルズ インコーポレイテッド ペプチド薬物の非経口注射用の安定な製剤
JP2016512255A (ja) 2013-03-14 2016-04-25 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インスリン‐インクレチン複合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
ZA200700708B (en) * 2004-06-29 2009-03-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CN101379069A (zh) * 2005-12-19 2009-03-04 塔夫茨大学信托人 软蛋白酶抑制剂及其前软形式
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
US9381292B2 (en) * 2014-07-24 2016-07-05 Kamal Ahmed ALJOHANI Diabetes regulator

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514990A (ja) 2002-12-27 2006-05-18 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物および方法
JP2014507484A (ja) 2011-03-10 2014-03-27 ゼリス ファーマシューティカルズ インコーポレイテッド ペプチド薬物の非経口注射用の安定な製剤
JP2016512255A (ja) 2013-03-14 2016-04-25 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インスリン‐インクレチン複合物

Also Published As

Publication number Publication date
US20250057923A1 (en) 2025-02-20
WO2018144867A1 (en) 2018-08-09
ES2944544T3 (es) 2023-06-22
JP2020505429A (ja) 2020-02-20
EP3576748A1 (en) 2019-12-11
US11357829B2 (en) 2022-06-14
US20200230211A1 (en) 2020-07-23
CN110446496A (zh) 2019-11-12
EP3576748B1 (en) 2023-04-05
EP4233876A1 (en) 2023-08-30
ES3040364T3 (en) 2025-10-30
US20220273771A1 (en) 2022-09-01
EP3576748A4 (en) 2020-11-04
CN117653715A (zh) 2024-03-08
EP4233876B1 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
US20220273771A1 (en) Systems, compositions and methods for treating diabetes
Heise The future of insulin therapy
US7192922B2 (en) Method of treating left ventricular dysfunction
RU2532378C2 (ru) Комбинация инсулина и агониста glp-1
EP3297653B1 (en) Treatment of post-bariatric hypoglycemia with glp-1 antagonists
DK3010530T3 (en) FIXED-FORMULATED FORMULATION BETWEEN INSULIN GLARGIN AND LIXISENATIDE
HK1046640A1 (zh) 用glp-1進行代謝介入以提高缺血和再灌注組織的功能
CA2369839A1 (en) Compositions of insulin and insulin-related peptide for treating diabetes
KR102694473B1 (ko) 제2형 진성 당뇨병 환자의 치료
Heinemann et al. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin
Umpierrez et al. Concentrated insulins: clinical update of therapeutic options
US20140249077A1 (en) Gel compositions
HK40099895B (en) Systems, compositions and methods for treating diabetes
HK40099895A (en) Systems, compositions and methods for treating diabetes
Ahrén Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control
US20230293639A1 (en) Systems, devices, compositions, and methods for treating diabetes
Sharma Emerging Injectable Therapies in Type 2 Diabetes Mellitus
Nauck Liraglutide, a once-daily human GLP-1 analogue
Potenza et al. Targeting the incretin system in type 2 diabetes mellitus
Nelson Use of Insulin, Pumps and Continuous Glucose Monitoring
Rigas et al. Therapy with GLP-1 agonists and dipeptidyl-peptidase IV inhibitors in type 2 diabetes mellitus
JP2024528457A5 (enExample)
Yin et al. Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: lessons for the cardiologist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220822

R150 Certificate of patent or registration of utility model

Ref document number: 7133229

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250